## **AMENDMENTS TO THE CLAIMS:**

This listing of claims replaces all earlier versions of claims in this application:

Claims 1-3 (Canceled)

4. (Currently Amended) A method for reducing the risk of onset of congestive heart failure in a patient not previously having congestive heart failure and who has an essentially maintained heart function, comprising administering to said the patient an effective amount of <u>ramipril or ramiprilat</u> an angiotensin converting enzyme inhibitor, wherein the patient is a human who exhibits normal or low blood pressure.

Claim 5 (Canceled)

6. (Currently Amended) [[A]] The method of claim 4, which comprises administering to the patient an effective amount of wherein the angiotensin converting enzyme inhibitor is alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzeylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril, epicaptopril, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabiciprilat, zofenopril, or zofenoprilat.

Claims 7-18 (Canceled)

19. (Currently Amended) [[A]] <u>The</u> method as claimed in claim 4, <u>which comprises</u> <u>administering to the patient an effective amount of wherein the angiotensin converting enzyme inhibitor is ramipril.</u>